Hematology

Data suggest the benefits of zanubrutinib versus acalabrutinib in R/R chronic lymphocytic leukemia were even more pronounced in high-risk cases.

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals.

The combination regimen is so effective because DAC has several mechanisms through which it exerts antileukemic effects.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.

Ameet Patel, MD, discusses scaling CAR T-cell therapy and bispecific therapies to improve access and potentially cure multiple myeloma.

A Quebec cohort study links gas station proximity to higher VOC exposure and elevated childhood cancer risk, especially acute lymphoblastic leukemia.

Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, discusses the growing role of real-world treatment data in CLL and other cancers.

Margaret Krackeler, MD, discusses real-world data supporting the switch from ibrutinib to zanubrutinib for chronic lymphocytic leukemia.

Disparities in access to allo-HCT for AML persist, highlighting the need for targeted interventions to ensure equitable treatment for all patients.

Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, enhancing patient safety and outcomes.

This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.

This approval brings the total indications for daratumumab and hyaluronidase to 5 in newly diagnosed disease and its 12th overall.

Ongoing phase 3 trials target improved therapies for hematologic malignancies, focusing on CLL, multiple myeloma, and pediatric leukemia outcomes.

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.

IGHV-unmutated CLL comprises 2 distinct epigenetic subtypes with different B-cell maturation signatures and genetic alterations, a study found.

Richter transformation with CNS involvement in CLL presents a poor prognosis, highlighting the need for tailored treatment strategies and further research.

Teclistamab was approved to treat relapsed/refractory multiple myeloma under the FDA’s accelerated approval pathway in October 2022.

Patients with mantle cell lymphoma experienced better survival rates when treated at academic centers compared with community facilities.

Frontline zanubrutinib regimens achieved objective response rates of 100% with deep remissions in older patients and younger, high-risk patients with MCL.

Bhavana (Tina) Bhatnagar, DO, discusses the transformative role of AI in enhancing patient care at West Virginia University Cancer Institute.

Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving patients in treatment decisions.

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.